A combination of two types of blood pressure-lowering drugs -- an angiotensin-converting enzyme inhibitor (ACEI) plus an angiotensin-receptor blocker (ARB), added to enzyme replacement therapy (ERT) ...
A major breakthrough to change the lives of cystic fibrosis sufferers. The trial looked at the treatment of patients with two copies of the F508DEL mutation which is carried by roughly half of all ...
Ingelheim, Germany, 3rd September, 2012 – New phase II data presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that combining tiotropium with olodaterol ...
Further tiotropium + olodaterol FDC data on patient outcomes such as quality of life are due to report later this year SAN DIEGO--(BUSINESS WIRE)--For media outside of the US, the UK & Canada only ...
The aim of our study was to investigate antiproliferative effects of PEP005 in a panel of colon cancer cell lines that expressed various levels of PKCδ and to evaluate the effects of PEP005-based ...
Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People With the Most Common Form of the Disease -13.17 mmol/L ...